Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.65 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644630 | 0.91 | GCK (0.73) | GCKSLC22A12KCNH2 | |
| SCHEMBL643360 | 0.89 | GCK (0.67) | GCKKCNH2 | |
| SCHEMBL2663581 | 0.87 | GCK (0.65) | GCKSLC22A12KCNH2NPC1RAB9A | |
| SCHEMBL644002 | 0.87 | GCK (0.65) | GCKSLC22A12KCNH2NPC1RAB9A | |
| SCHEMBL644628 | 0.86 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL642661 | 0.86 | GCK (0.68) | GCKSLC22A12KCNH2NPC1RAB9A | |
| SCHEMBL644289 | 0.86 | GCK (0.68) | GCKKCNH2NPC1RAB9A | |
| SCHEMBL9923286 | 0.85 | GCK (0.67) | GCKKCNH2NPC1RAB9A | |
| SCHEMBL644232 | 0.84 | GCK (0.85) | GCKKCNH2NPC1RAB9A | |
| SCHEMBL642638 | 0.84 | GCK (0.68) | GCKKCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | GCK 1/4885SLC22A12 1016/4885AR 1424/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | GCK 1/4885SLC22A12 1016/4885AR 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.